Rocket Lab's Two-Speed Reality: Record Orders Meet a Market That's Moved On

Rocket Lab's record revenue and backlog can't offset investor fears over its $8B Iridium acquisition financing, as shares drop 36% in a month.

There is a peculiar disconnect playing out in Rocket Lab's corner of the space economy. The company is booking contracts at a pace it has never seen before, its revenue is at an all-time high, and yet its share price has been cut down by more than a third in a single month. Wall Street's consensus price target still implies roughly 80 percent upside from current levels, but the market is clearly not listening.

The tension is not hard to diagnose. Rocket Lab's operational engine is humming, but investors have shifted their gaze to something else entirely: an $8 billion acquisition that has suddenly become far more complicated to finance.

The Numbers Tell One Story

The first quarter was, by any measure, a standout. Revenue climbed roughly 63 percent year over year to a record $200.3 million, while the backlog swelled to $2.2 billion—a jump of about 20 percent in just three months. Management has guided to another record quarter ahead, with second-quarter revenue expected to land between $225 million and $240 million.

The order flow has only accelerated since. The U.S. Space Force awarded the company a $266 million contract for twelve suborbital missions from its Kodiak, Alaska launch site, with options for six more through 2028—the largest award of its kind in the company's history. Days later, Japanese satellite operator iQPS signed its third multi-launch agreement within a year, covering three Electron missions starting in late 2027.

None of this has moved the needle. The stock closed the week at €56.30, down 36 percent over the prior 30 days and nearly 58 percent below its May peak of €133.80. At that high-water mark, the shares had touched a 52-week record; the subsequent slide has been steep enough to leave the stock trading roughly 32 percent below its 50-day moving average and about 16 percent under its 200-day average of €67.37.

The Deal That Changed Everything

The catalyst for the sell-off arrived in late June, when Rocket Lab announced its intention to acquire satellite operator Iridium Communications in a deal valued at around $8 billion. Iridium shareholders are set to receive $54 per share—half in cash, half in Rocket Lab stock via an exchange ratio with a collar that begins at $67.50.

That collar is now the crux of the problem. Rocket Lab's shares have fallen below the lower bound of that range, turning the equity component of the financing into a live question mark. Investors are left to puzzle over how the transaction will ultimately be priced, and whether the company's shareholders will bear the cost of the shortfall.

The balance sheet adds another layer of concern. Rocket Lab burned through $321.8 million in free cash flow during fiscal 2025, and the first quarter alone saw the company raise an additional $450 million through an at-the-market equity program. That fresh capital underscores just how thirsty the business is for liquidity as it tries to fund both the Iridium acquisition and the development of its next-generation rocket.

Neutron's Long Shadow

The other weight on the stock is the Neutron program. The Electron rocket remains the most-launched small vehicle in its class—it set a new record in June with a 16-hour turnaround for the Space Force's VICTUS-HAZE mission—but investors have long since moved past it. Neutron is the vehicle that could transform Rocket Lab from a niche small-satellite launcher into a genuine rival to SpaceX, and its first flight is now scheduled for no earlier than the fourth quarter of 2026.

That timeline is the problem. Investors are being asked to pay a premium valuation for a company whose defining catalyst is still months away. At a price-to-sales ratio of 54 and a market capitalization of €35.11 billion, the market is pricing in a future that has not yet arrived. The stock's annualized volatility of nearly 96 percent suggests the market is struggling to settle on a fair value in the interim.

Analysts Hold the Line

The analyst community has largely maintained its bullish posture. Piper Sandler initiated coverage with a Neutral rating and an $83 price target, citing the rich valuation. KGI Securities upgraded the stock to Outperform in late July with a target of $107, while Bank of America reaffirmed its Buy rating with a $115 objective. The average consensus price target sits near $106—roughly 77 percent above Friday's close, according to the most recent calculations.

Technical indicators suggest the selling may be exhausting itself. The relative strength index has fallen to 36.7, edging into oversold territory. But the chart remains damaged, and the path back to the May highs is a long one.

What Comes Next

The next real test arrives on August 10, 2026, when Rocket Lab reports second-quarter results after the U.S. market close. It will be the first comprehensive earnings report since the Iridium announcement, offering investors a fresh look at revenue momentum, cash reserves, and any progress on Neutron's development timeline.

For now, the stock sits suspended between two competing narratives. One portrays a company with record growth, a dominant position in small launch, and more than €2 billion in liquidity. The other depicts a business whose biggest bet is suddenly straining under financing pressure, with a flagship rocket that remains grounded until further notice. The earnings report will determine which story wins out—but until then, Rocket Lab remains a waiting game with unusually high stakes.